Abstract 62P
Background
According to the GLOBOCAN database 2020, colorectal cancer (CRC) has the fourth-highest incidence in Indonesia. In Yogyakarta province, CRC is the third most prevalent cancer. CRC usually present with common gastrointestinal complaints. The relationship between the chief complaint and clinicopathology parameters has been rarely explored in Indonesia. We, therefore, aimed to analyze their association with our CRC patients.
Methods
A retrospective study was done on 1,276 CRC cases diagnosed between January 2016 and December 2019 at Dr. Sardjito Hospital, Yogyakarta. We collected secondary data from the CRC clinical registry database, including demography, chief complaints and clinicopathology features. Data on hospitals where CRC diagnostic procedure was performed based on biopsy or resection. Chi-square analysis was used to determine the relationship between the chief complaint and clinicopathology parameters.
Results
The most common chief complaints were hematochezia (34.4.%), bloating (24.8%), constipation (23%), diarrhea (17.5%), weight loss (12.1%) and abdominal mass (9.8%). Hematochezia was associated with tumor site, T status, N status, M status, clinical stage, performance status, and type of diagnostic hospital. Diarrhea was associated with age, hemoglobin, serum albumin, and type of diagnostic hospital. Constipation was associated with gender, tumor site, N status, serum albumin, and type of diagnostic hospital. Bloating was associated with tumor site, M status, clinical stage, histological grade, serum albumin, performance status, and type of diagnostic hospital. Weight loss was related to the tumor site, M status and diagnostic hospital. Abdominal mass was associated with age, gender, and serum albumin. All p values were < 0.05.
Conclusions
The chief complaints of CRC were associated with various clinicopathological parameters that may influence the patient's prognosis. Because complaints associated with CRC are similar to other gastrointestinal diseases, the awareness of clinicians to immediately follow up is needed so that patients can be identified at an earlier stage. Referral process across hospitals may also serve as a target for health system improvement.
Clinical trial identification
Editorial acknowledgement
The authors thank Yana Suryani, Rosita Yunanda Purwanto, and Nugira Dinantia for technical assistance and coordination.
Legal entity responsible for the study
Yasjudan Rastrama Putra.
Funding
The authors received financial support from the Applied Research Grant 2020–2021, The Indonesian Ministry of Research, Technology, and Higher Education and the Institutional Links grant, ID 527558574, under the Newton Institutional Link-Indonesia KLN Fund partnership, funded by the UK Department for Business, Energy and Industrial Strategy and Indonesia Ministry of Research Technology & Higher Education and delivered by the British Council.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
119P - Clinicopathological features and roles of lymph node metastases in gastric cancer: A single-center retrospective study in China
Presenter: yuming zhang
Session: Poster viewing 02
120P - Clinical implication of DNA damage response gene in advanced gastric cancer stage IV and recurrent gastric cancer patients after gastrectomy treated palliative chemotherapy
Presenter: In Gyu Hwang
Session: Poster viewing 02
121P - Treatment patterns and outcomes of recurrent/metastatic esophageal cancer: Real-world data
Presenter: Amrith B P
Session: Poster viewing 02
122P - Efficacy and safety of mFOLFOX-6 in advanced gastric cancer: A prospective observational study
Presenter: Amrith B P
Session: Poster viewing 02
123P - Sarcomatoid carcinoma of gall bladder: A series of 14 cases from a single tertiary-care oncology centre
Presenter: Subhash Yadav
Session: Poster viewing 02
124P - Clinical profile and treatment outcomes of hepatocellular carcinoma from a tertiary care hospital in South India: A retrospective study
Presenter: Gayathri Nair
Session: Poster viewing 02
125P - A parametric network meta-analysis of PD-1 inhibitors in second-line treatment for advanced esophageal squamous cell carcinoma
Presenter: Shubhram Pandey
Session: Poster viewing 02
126P - Late line FOLFOX therapy after prior cisplatin-based regimen in advanced esophageal squamous cell carcinoma: A multi-institutional retrospective study
Presenter: Keitaro Shimozaki
Session: Poster viewing 02
127P - LABS score: The prognostic tool for advanced hepatocellular carcinoma treated with FOLFOX4 and real-world efficacy from a single-center retrospective study
Presenter: Jirapat Wonglhow
Session: Poster viewing 02
128P - Survival outcome of gastric cancer patients in a tertiary care center: A 10-year single center retrospective study
Presenter: Dawn Lynn Guardiario
Session: Poster viewing 02